Pathogenesis and management of lipoprotein disorders.
D000012:Abetalipoproteinemia / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002914:Chylomicrons / Q000378:metabolism; D003084:Colestipol / Q000627:therapeutic use; D004041:Dietary Fats / Q000008:administration & dosage; D005260:Female; D015248:Gemfibrozil; D006801:Humans; D008072:Hyperlipoproteinemia Type I / Q000628:therapy; D006938:Hyperlipoproteinemia Type II / Q000175:diagnosis / Q000628:therapy; D006952:Hyperlipoproteinemia Type III / Q000175:diagnosis / Q000628:therapy; D006953:Hyperlipoproteinemia Type IV / Q000175:diagnosis / Q000628:therapy; D006954:Hyperlipoproteinemia Type V / Q000628:therapy; D006951:Hyperlipoproteinemias / Q000378:metabolism / Q000628:therapy*; D006995:Hypobetalipoproteinemias / Q000378:metabolism; D007009:Hypolipoproteinemias / Q000378:metabolism / Q000628:therapy*; D007223:Infant; D007231:Infant, Newborn; D008075:Lipoproteins, HDL / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use; D010421:Pentanoic Acids / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use; D013631:Tangier Disease / Q000378:metabolism
D002914:Chylomicrons; D004041:Dietary Fats; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010421:Pentanoic Acids; D002792:Cholestyramine Resin; D009525:Niacin; D003084:Colestipol; D011341:Probucol; D015248:Gemfibrozil